Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at Rodman & Renshaw 12th Annual Healthcare Conference

CHARLOTTE, N.C., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Rodman & Renshaw 12th Annual Healthcare Conference at 11:40...
August 26, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces FDA Approval of CH-4051 Phase II Protocol

CHARLOTTE, N.C., Aug. 26, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase...
August 19, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Initiation of Investigator-Led Phase II Study of Droxidopa in Chronic Fatigue Syndrome

CHARLOTTE, N.C., Aug. 19, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic...
July 27, 2010 16:05 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Second Quarter 2010 Results

Top-line Data from Pivotal Phase III Northera Study 301 in Neurogenic Orthostatic Hypotension Expected In September 2010 Full Enrollment of Northera Study 306 on Track for Completion by Year...
July 21, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Host Conference Call to Discuss Second Quarter 2010 Results

CHARLOTTE, N.C., July 21, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release second quarter results for the period ended June 30, 2010 after...
July 01, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Positive Interim Analysis of Phase II Trial of Droxidopa in Fibromyalgia

Independent Data Monitoring Committee Sees Meaningful Efficacy in Multiple Treatment Arms Trial Focusing on Novel Droxidopa/Carbidopa Combination Therapy No Significant Adverse Events or...
June 30, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Achieves Target Enrollment in Phase III Trial of Northera in Neurogenic Orthostatic Hypotension

Top-line Data Expected in Q3 10 CHARLOTTE, N.C., June 30, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has successfully reached its target enrollment of 150...
June 29, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Initiates Northera Study 306 in Neurogenic Orthostatic Hypotension Associated With Parkinson's Disease and Provides Update on Status of Phase II Study of CH-4051 in Rheumatoid Arthritis

CHARLOTTE, N.C., June 29, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of...
June 22, 2010 08:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at Sidoti Semiannual Micro Cap Conference

CHARLOTTE, N.C., June 22, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Sidoti & Company 2010 Semiannual Micro-Cap Conference on...
June 17, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Presents Data at 14th International Congress on Parkinson's Disease and Movement Disorders

Clinical Review Highlights Neuroprotective Potential of Norepinephrine in Parkinson's Disease Northera, an Orally Available Norepinephrine Pro-drug, Significantly Improves Symptoms of...